2018 AANS Annual Scientific Meeting-513. Glioma Stem Cells Driven by Distinct BMI-1 and EZH2 Transcriptional Pathways Targeted Separately or Synergistically

513. Glioma Stem Cells Driven by Distinct BMI-1 and EZH2 Transcriptional Pathways Targeted Separately or Synergistically

Back to course

Video Transcription

Video Summary

In this video presentation, Dr. Sloan discusses the challenges of treating gliomas, a type of malignant brain tumor. He explains that treatment resistance is commonly attributed to glioma stem cells and intratumoral heterogeneity. Glioma stem cells, comprising a small percentage of the tumor, have the ability to self-renew and propagate the tumor. By targeting these stem cells, it may be possible to achieve sustained remission. Dr. Sloan's research involved characterizing distinct regions of gliomas and their corresponding glioma stem cells. He found that targeting specific molecular markers in combination was more effective than targeting them individually. Additionally, epigenetic profiling revealed differences in gene expression between regions. Inhibiting certain transcriptional regulators improved the survival rate of animal models. This research suggests that targeting multiple glioma stem cell niches simultaneously may lead to improved treatment outcomes. Dr. Sloan acknowledges his collaborators and funding sources.

Asset Caption

Andrew E. Sloan, MD, FAANS

Keywords

gliomas

malignant brain tumor

treatment resistance

glioma stem cells

intratumoral heterogeneity